Fluconazole therapy for histoplasmosis

Clinical Infectious Diseases

Volumn 23, Issue 5, 1996, Pages 996-1001

  McKinsey, David S ^a   Kauffman, Carol A ^b   Pappas, Peter G ^b   Cloud, Gretchen A ^b   Girard, William M ^b   Sharkey, Patricia K ^b   Hamill, Richard J ^b   Thomas, Carolynn J ^b   Dismukes, William E ^b  

^a Research Medical Center Brookside Campus   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029910025     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.5.996     Document Type: Article

References (15)

1. Wheat J. Histoplasmosis: recognition and treatment. Clin Infect Dis 1994; 19(suppl 1):S19-27.
2. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
3. Hawkins SS, Gregory, DW, Alford RH. Progressive disseminated histoplasmosis: favorable response to ketoconazole. Ann Intern Med 1981;95:446-9.
4. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985;103:861-72.
5. Dismukes WE, Stamm AM, Graybill JR, et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases Collaborative Antifungal Study. Ann Intern Med 1983;98:13-20.
6. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992;93:489-97.
7. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-42.
8. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6.
9. Kobayashi GS, Travis S, Medoff G. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother 1986;29:660-2.
10. Kobayashi GS, Travis SJ, Medoff G. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob Agents Chemother 1987;31:2005-6.
11. Graybill JR, Palou E, Ahrens J. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis 1986;134:768-70.
12. Sharkey-Mathis PK, Velez J, Fetchick R, Graybill JR. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr 1993;6:809-19.
13. Norris S, Wheat J, McKinsey D, et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994;96:504-8.
14. Bridge KS, Goodpasture HC. Disseminated histoplasmosis treated with fluconazole. Kansas Med 1994;95:113-5.
15. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990;12 (suppl 3):S349-63.